argenx SE (EBR:ARGX)
Belgium · Delayed Price · Currency is EUR | Market Cap | 44.50B +39.7% |
| Revenue (ttm) | 4.11B +79.4% |
| Net Income | 1.29B +39.9% |
| EPS | 19.51 +41.1% |
| Shares Out | 62.19M |
| PE Ratio | 36.68 |
| Forward PE | 28.24 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 402,749 |
| Open | 718.20 |
| Previous Close | 719.00 |
| Day's Range | 714.00 - 723.20 |
| 52-Week Range | 456.60 - 810.00 |
| Beta | -0.06 |
| Analysts | Strong Buy |
| Price Target | 846.68 (+18.32%) |
| Earnings Date | May 7, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial numbers in USD Financial StatementsNews
argenx to Host Myositis R&D Webinar on June 23, 2026
May 28, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today anno...
argenx SE Transcript: Bank of America Global Healthcare Conference 2026
FDA leadership turnover and regulatory uncertainty dominate the policy landscape, with drug pricing reforms and MFN agreements creating long-term industry vulnerabilities. China’s rise in biopharma is accelerating, prompting bipartisan concern but limited immediate legislative action. Expect regulatory focus and oversight to increase post-election, with major reforms unlikely this year.
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and tr...
argenx SE Earnings Call Transcript: Q1 2026
Q1 2026 saw 63% revenue growth to $1.3B, strong operating leverage, and expanding VYVGART adoption in MG and CIDP. Pipeline progress and label expansions are set to drive further growth, with robust cash reserves supporting continued investment.
argenx SE Earnings release: Q1 2026
argenx SE released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
argenx SE Slides: Q1 2026
argenx SE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
argenx to Present at BofA Securities 2026 Health Care Conference
May 6, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou...
argenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive Officer
Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of peo...
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
April 30, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today an...
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, O...
eClinical Solutions elluminate® Platform Supports argenx to Enhance Data Oversight and Efficiency
BOSTON--(BUSINESS WIRE)--eClinical Solutions LLC, a global provider of digital clinical software and services, today announced that argenx SE, a global immunology company, is expanding adoption of the...
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Positive results from Phase 3 ADAPT OCULUS study show VYVGART's potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of pat...
argenx SE Transcript: TD Cowen 46th Annual Health Care Conference
The discussion outlined a robust growth and innovation strategy, with near-term clinical readouts in myositis, MMN, and Sjögren's, and a strong FcRn franchise expansion. VYVGART maintains leadership in MG, while new programs and flexible dosing aim to address unmet needs and broaden market reach.
argenx SE Earnings Call Transcript: Q4 2025
Achieved 90% year-over-year net sales growth to $4.2B in 2025, driven by strong VYVGART adoption and label expansion opportunities in MG and CIDP. Positive phase III ocular MG results and robust pipeline support long-term growth and profitability.
argenx SE Annual report: Q4 2025
argenx SE has published its Q4 2025 annual report on February 26, 2026.
argenx SE Annual report: Q4 2025
argenx SE has published its Q4 2025 annual report on February 26, 2026.
argenx SE Earnings release: Q4 2025
argenx SE released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
argenx SE Slides: Q4 2025
argenx SE has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year ‑ over ‑ year growth
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
Study met primary endpoint (p-value = 0.012) First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics ...
argenx to Present at TD Cowen 46th Annual Healthcare Conference
February 23, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
January 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx SE Transcript: 44th Annual J.P. Morgan Healthcare Conference
VYVGART continues to drive strong patient outcomes and commercial growth, with 19,000 patients treated and significant expansion into new indications like seronegative and ocular MG. The pipeline is robust, with multiple late-stage assets and innovative therapies advancing, supporting ambitious 2030 impact goals.
argenx SE Slides: 44th Annual J.P. Morgan Healthcare Conference
argenx SE has posted slides in relation to its latest quarterly earnings report, which was published on January 12, 2026.
argenx Highlights 2026 Strategic Priorities
Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales